ArticleInternational journal of clinical and experimental pathology2019
Expression of FANCD2 is associated with prognosis in patients with nasopharyngeal carcinoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case-Control Study.Hematology reports · 2024Article
- Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma.Oncogenesis · 2021Article
- Cross-link between ferroptosis and nasopharyngeal carcinoma: New approach to radiotherapy sensitization.Oncology letters · 2021Review
- Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective.Frontiers in cell and developmental biology · 2021Review
- Homozygous Mutation in the FANCD2 Gene Observed in a Saudi Male Infant with Severe Ambiguous Genitalia.Case reports in endocrinology · 2021Article
- FANCD2 Confers a Malignant Phenotype in Esophageal Squamous Cell Carcinoma by Regulating Cell Cycle Progression.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between Fanconi anemia complementation group D2 (FANCD2) and early diagnosis, pathogenesis, recurrence, and prognosis in patients with nasopharyngeal carcinoma (NPC) was investigated in a retrospective case-control study. The clinicopathological data of patients with NPC were collected. The results showed that FANCD2 was significantly higher in poorly differentiated squamous cell carcinoma than in moderately and well differentiated carcinoma. FANCD2 was significantly lower in recurrent NPC tissues than in NPC tissues before treatment. FANCD2 was markedly higher in T
Indexed as
Identifiers
31934192PMC6949855W3012368465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.